Organogenesis Holdings Inc. Class A Stock News

Simply stated, we believe our second-quarter revenue performance is a direct result of the organization's resilience in the face of these unprecedented challenges and the dedication of our employees t

BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report) yesterday and set a price

Organogenesis (ORGO) delivered earnings and revenue surprises of 58.33% and 0.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

CANTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

Organogenesis (ORGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wells Fargo & Company MN reduced its stake in shares of Organogenesis Holdings Inc (NASDAQ:ORGO) by 41.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange

CANTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of pr

Organogenesis (NASDAQ:ORGO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, �

In a report released yesterday, Steven Lichtman from Oppenheimer assigned a Buy rating to Organogenesis Holdings (ORGO – Research Report),

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report),

CANTON, Mass., July 15, 2020 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.

While normal hospital operations look set to resume, patients remain concerned about seeking care but analysts are optimistic for a recovery in elective procedures post-coronavirus.

ACell has filed to raise $75 million from an IPO of its common stock. The firm develops and sells various wound care products.

Alliancebernstein L.P. acquired a new stake in Organogenesis Holdings Inc (NASDAQ:ORGO) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The f